CA-FOCAL-SYSTEMS
16.3.2022 18:58:07 CET | Business Wire | Press release
On their mission to automate and optimize brick and mortar retail with state-of-the-art AI and deep learning, Focal Systems is proud to announce the launch of the world’s first “Self-Driving Store”-Operating System powered by computer vision and AI, called FocalOS. After 7 years hardening the platform with the largest retailers in the world, Focal's “Self-Driving Store”-Operating System is now Generally Available.
Enabled by AI-powered Shelf Cameras, FocalOS leverages computer vision and deep learning technology to provide real-time shelf digitization. This digitization feeds FocalOS, which automates order writing and ordering, directs stockers to double their productivity, optimizes category management on a per store basis, manages e-comm platforms to eliminate substitutions, tracks productivity per associate to drive further efficiencies, and much more. With FocalOS, corporate leaders can "teleport" into any store from anywhere in the world in seconds to see exactly what their shelves look like and how their stores are performing.
Major retailers have proven >50x ROI with FocalOS, making this the most profitable investment in all of retail technology.
Francois Chaubard, Founder and CEO, will unveil this solution in depth at the FMI Midwinter Conference in Orlando, Fla. on March 29.
Retailers have incredibly challenging jobs. Managing thousands of SKUs, employees, stores and ecommerce, while facing rising labor and supply chain costs and the evergreen battle for market share. Since 2015 our team has worked with leading global retailers to invent and implement AI solutions that drive true innovation, transformative financial returns and happy customers.
-Francois Chaubard - Founder/CEO Focal Systems
Focal has worked with leading retailers across North America, Europe and Australia and deployed more than 50,000 cameras worldwide. This launch enables retailers the ability to run fully automated “Self-Driving Stores" that achieve unprecedented labor efficiencies and sales growth just by setting the store on "Cruise Control" and letting the AI take it from there.
We’re always striving for more ways to improve the shopping experience for our customers. Focal is helping us use technology to improve our on-shelf customer availability, so our customers can find what they are looking for each time they choose to shop in-store with us.”
-Sam Wankowski - Chief Operations Officer, Walmart Canada
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state of the art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”-Operating System that revolutionizes how stores are run. Focal has raised more than $40m to date, and scaled their solutions to three continents and hundreds of stores, with thousands of cameras deployed. The Focal team is a carefully selected group of retail operations and AI experts who together have designed the next generation of operating systems for brick and mortar retail that leverages state-of-the-art AI and retail best practices to automate and optimize brick and mortar and on-line stores today.
Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom